Researchers at Provincial Health Services Authority (PHSA) and University of British Columbia have identified radiolabeled compounds targeting glutamate carboxypeptidase II (NAALADase; NAAG peptidase, FOLH1; PSMA) acting as positron-emission tomography (PET) imaging agents with low uptake in salivary glands and kidneys reported to be useful for the diagnosis of prostate cancer. 

Floratek GmbH has synthesized cationic chromenones reported to be useful for the treatment of cancer.

Kyung Hee University has disclosed microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors acting as prostaglandin E2 (PGE2) production inhibitors reported to be useful for the treatment of asthma, atherosclerosis, diabetes, pain, osteoporosis, bursitis, infections and cancer.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Heptares Therapeutics Ltd. has divulged pyrrolidine-2-carboxamide derivatives and morpholine-3-carboxamide derivatives acting as prostaglandin E2 receptor EP4 subtype (PTGER4; EP4) agonists reported to be useful for the treatment of gastrointestinal and respiratory disorders.

Scientists at Johns Hopkins University and The Lieber Institute for Brain Development have identified peripherally restricted GABA(A) receptor subunits α3β2γ2S (GABRA3) positive allosteric modulators reported to be useful for the treatment of inflammatory bowel disease, lactose intolerance and abdominal pain.

Arvinas Operations Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety covalently linked to a non-receptor tyrosine-protein kinase TYK2-targeting moiety via linker.

Iambic Therapeutics Inc. has disclosed quinazoline compounds acting as cyclin-dependent kinase (CDK) inhibitors, particularly CDK2 and/or CDK4 and/or CDK6 inhibitors reported to be useful for the treatment of ovarian and breast cancer.

Henan Medinno Pharmaceutical Technology Co. Ltd. has synthesized TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of cancer, aging, arteriosclerosis, diabetic nephropathy, Alzheimer’s disease, viral infections, osteoporosis and skin fibrosis, among others.

Blacksmith Medicines Inc. has disclosed UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors reported to be useful for the treatment of Pseudomonas aeruginosa infection.